Avalo Therapeutics
D

AVTX

6.75500
USD
-0.17
(-2.45%)
قبل الجلسة·6.77000USD+0.01500(+0.22%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
82
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
362,270,576

العنوان: Avalo Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.